- Tytuł:
- 67 - Efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): RATIONALE 303
- Autorzy:
- Źródło:
- In Lung Cancer March 2022 165 Supplement 1:S32-S33
Czasopismo naukowe